THE TABLET

• Vol. 2 No. 8 Benzodiazepine Use for Delirium in Palliative Care
• Vol. 2 No. 7 Benzodiazepine Class Review
• Vol. 1 No. 18 Review of Antipsychotic Characteristics to Aid in Antipsychotic Selection

• Vol. 4 No. 3 Mirtazapine for Cancer Associated Anorexia and Cachexia
• Vol. 3 No. 7 Olanzapine for Chemo Related Anorexia
• Vol. 3 No. 1 UPMC Research on Olanzapine Use
• Vol. 1 No. 18 Review of Antipsychotic Characteristics to Aid in Antipsychotic Selection
• Vol. 1 No. 14 Transdermal Fentanyl (TDF) use in Cachectic Cancer Patients
• Vol. 1 No. 12 Mirtazapine for Cancer Associated Anorexia and Cachexia
• Vol. 1 No. 1 Benzodiazepines for Appetite Stimulation

• Vol. 2 No. 12 Lavender Oil for Insomnia in Palliative Care
• Vol. 2 No. 9 Antidepressant Class Review
• Vol. 2 No. 7 Benzodiazepine Class Review
• Vol. 1 No. 18 Review of Antipsychotic Characteristics to Aid in Antipsychotic Selection
• Vol. 1 No. 8 Antidepressant Adverse Drug Reactions: Focus on QT Prolongation

• Vol. 3 No. 18 Cannabis Withdrawal and How to Address It
• Vol. 3 No. 11 CBD Oil in Palliative Care, RCT
• Vol. 2 No. 5 Cannabis Hyperemesis Syndrome
• Vol. 1 No. 25 Medical Cannabis for Pain, Review of the Evidence
• Vol. 1 No. 20 Drug Interactions with Medical Cannabis

• Vol. 1 No. 22 Opioid-Induced Constipation Evidence Spotlight
• Vol. 1 No. 21 Opioid-Induced Constipation Treatment Review

• Vol. 3 No. 13 Anticholinergic Burden in PC
• Vol. 1 No. 30 Anticholinergic Burden in Palliative Care
• Vol. 1 No. 29 Implications of Polypharmacy in Palliative Care

• Vol. 3 No. 1 UPMC Research on Olanzapine Use
• Vol. 2 No. 16 Valproic Acid for Delirium
• Vol. 2 No. 8 Benzodiazepine Use for Delirium in Palliative Care
• Vol. 2 No. 6 Dexmedetomidine for Terminal Delirium
• Vol. 1 No. 18 Review of Antipsychotic Characteristics to Aid in Antipsychotic Selection

• Vol. 3 No. 20 UPMC Quality Improvement: Pilot Palliative Care Pharmacist-led Opioid Deprescribing Clinic: Feasibility, Safety, and Efficacy
• Vol. 1 No. 17 Atrial Fibrillation, Functionality, and Anticoagulation

• Vol. 3 No. 9 Antidepressant Rotation Strategies
• Vol. 3 No. 6 New Medication Review Auvelity dextromethorphan HBr/ bupropion HCI
• Vol. 2 No. 9 Antidepressant Class Review
• Vol. 2 No. 4 Neuroendocrine Tumors and Antidepressants
• Vol. 1 No. 15 Bupropion (Wellbutrin®) for Cancer-Related Fatigue
• Vol. 1 No. 12 Mirtazapine for Cancer Associated Anorexia and Cachexia
• Vol. 1 No. 8 Antidepressant Adverse Drug Reactions: Focus on QT Prolongation

• Vol. 2 No. 3 Managing Cancer Treatment-Related Dysgeusia

• Vol. 3 No. 19 Opioids for Terminal Dyspnea: Comparable Effectiveness of Opioids?
• Vol. 3 No. 10 Opioids for Dyspnea
• Vol. 2 No. 10 Fentanyl for Dyspnea in Palliative Care Patients

• Vol. 5. No. 5 New Medication Review Solriamfetol
• Vol. 3 No. 16 Self Acupressure for Symptom Control in Cancer
• Vol. 2 No. 13 Ginseng for Cancer-Related Fatigue
• Vol. 1 No. 24 Dexamethasone for Cancer-Related Fatigue
• Vol. 1 No. 23 As Needed Methylphenidate for Cancer-Related Fatigue
• Vol. 1 No. 15 Bupropion (Wellbutrin®) for Cancer-Related Fatigue

• Vol. 2 No. 2 Opioid-Induced Hyperalgesia (OIH) in Chronic Pain
• Vol. 2 No. 1 Dexmedetomidine for Opioid-Induced Hyperalgesia (OIH)

• Vol. 4 No. 1 Dual Orexin Receptor Antagonists (DORAs) for Chronic Insomnia
• Vol. 3 No. 16 Self Acupressure for Symptom Control in Cancer
• Vol. 3 No. 5 New Medication Review Quviviq daridorexant for Insomnia
• Vol. 3 No. 1 UPMC Research on Olanzapine Use
• Vol. 2 No. 12 Lavender Oil for Insomnia in Palliative Care
• Vol. 2 No. 7 Benzodiazepine Class Review
• Vol. 1 No. 18 Review of Antipsychotic Characteristics to Aid in Antipsychotic Selection

• Vol. 3 No. 9 Antidepressant Rotation Strategies

• Vol. 5. No. 1 UPMC Research PAMORA Use in Palliative Care 
• Vol. 3 No. 16 Self Acupressure for Symptom Control in Cancer
• Vol. 3 No. 1 UPMC Research on Olanzapine Use
• Vol. 2 No. 15 Aprepitant (Emend®) for Refractory Nausea
• Vol. 2 No. 14 Transmucosal Drug Delivery: A Focus on Opioids
• Vol. 2 No. 5 Cannabis Hyperemesis Syndrome
• Vol. 1 No. 18 Review of Antipsychotic Characteristics to Aid in Antipsychotic Selection
• Vol. 1 No. 5 Antiemetic Adverse Drug Reactions: Focus on QTc Prolongation

• Vol. 4 No. 6 Honey for Oral Mucositis
• Vol. 3 No. 2 Ketamine for Oral Mucositis
• Vol. 1 No. 33 Oral Indomethacin Spray for Oral Mucositis Pain

• Vol. 4 No. 2 Duloxetine (Cymbalta®) for Osteoarthritis Pain

• Vol. 5. No. 10 Acute Pain Management in the Setting of Methadone or Buprenorphine Use
Vol. 3 No. 16 Self Acupressure for Symptom Control in Cancer
• Vol. 3 No. 15 Acetaminophen as Adjunct with High OMEs
• Vol. 3 No. 12 Drug Interactions and Opioids
• Vol. 3 No. 3 IV Acetaminophen for Acute Pain: How Does It Compare to Other Analgesics?
• Vol. 2 No. 14 Transmucosal Drug Delivery: A Focus on Opioids
• Vol. 2 No. 11 Methocarbamol for Acute Pain
• Vol. 1 No. 16 Dementia, Pain and Neuropsychiatric Behaviors
• Vol. 1 No. 14 Transdermal Fentanyl (TDF) use in Cachectic Cancer Patients
• Vol. 1 No. 13 Intravenous Patient Controlled Analgesia (PCA)

• Vol. 5. No. 3 New Medication Review Suzetrigine 
• Vol. 5. No. 6 New Medication Review Roxybond
• Vol. 5. No. 7 Opioid Conversion Guidelines in Cancer
• Vol. 4. No. 19 Memantine (Namenda) for Pain
• Vol. 3 No. 16 Self Acupressure for Symptom Control in Cancer
• Vol. 3 No. 12 Drug Interactions and Opioids
• Vol. 2 No. 14 Transmucosal Drug Delivery: A Focus on Opioids
• Vol. 2 No. 2 Opioid-Induced Hyperalgesia (OIH) in Chronic Pain
• Vol. 1 No. 31 Oral Ketamine for Pain
• Vol. 1 No. 28 Buprenorphine for Chronic Pain
• Vol. 1 No. 16 Dementia, Pain and Neuropsychiatric Behaviors
• Vol. 1 No. 14 Transdermal Fentanyl (TDF) use in Cachectic Cancer Patients
• Vol. 1 No. 13 Intravenous Patient Controlled Analgesia (PCA)
• Vol. 1 No. 7 New Literature: Methadone IV to PO Conversion
• Vol. 1 No. 4 Another Tool in your Palliative Care Toolbox: Lidocaine Series Part 3
• Vol. 1 No. 3 Another Tool in your Palliative Care Toolbox: Lidocaine Series Part 2
• Vol. 1 No. 2 Another Tool in your Palliative Care Toolbox: Lidocaine Series Part 1

• Vol. 5. No. 8 Low Dose Naltrexone for Analgesia
• Vol. 5. No. 9 Calcitonin Use in Pain Management
• Vol. 4. No. 20 UPMC Research Ketamine Use in Palliative care
• Vol. 4 No. 4 IV Ketamine in Palliative Care (a focus on Pain): Review of the Evidence
• Vol. 3 No. 16 Self Acupressure for Symptom Control in Cancer
• Vol. 3 No. 15 Acetaminophen as Adjunct with High OMEs
• Vol. 3 No. 12 Drug Interactions and Opioids
• Vol. 3 No. 8 Moxibustion as Adjuvant Therapy for Cancer Pain
• Vol. 2 No. 14 Transmucosal Drug Delivery: A Focus on Opioids
• Vol. 1 No. 31 Oral Ketamine for Pain
• Vol. 1 No. 16 Dementia, Pain and Neuropsychiatric Behaviors
• Vol. 1 No. 14 Transdermal Fentanyl (TDF) use in Cachectic Cancer Patients
• Vol. 1 No. 13 Intravenous Patient Controlled Analgesia (PCA)
• Vol. 1 No. 4 Another Tool in your Palliative Care Toolbox: Lidocaine Series Part 3
• Vol. 1 No. 3 Another Tool in your Palliative Care Toolbox: Lidocaine Series Part 2
• Vol. 1 No. 2 Another Tool in your Palliative Care Toolbox: Lidocaine Series Part 1

• Vol. 4. No. 18 Gabapentinoid Rotation to Duloxetine for Neuropathic Pain
• Vol. 4 No. 5 Gabapentin: Updated Safety Concerns
• Vol. 3 No. 16 Self Acupressure for Symptom Control in Cancer
• Vol. 3 No. 12 Drug Interactions and Opioids
• Vol. 3 No. 4 Chemotherapy-Induced Peripheral Neuropathy Review of the Evidence
• Vol. 2 No. 14 Transmucosal Drug Delivery: A Focus on Opioids
• Vol. 2 No. 9 Antidepressant Class Review
• Vol. 1 No. 32 Gabapentin and Opioid Co-Administration
• Vol. 1 No. 31 Oral Ketamine for Pain
• Vol. 1 No. 27 Neuropathic Agents Onset of Analgesia
• Vol. 1 No. 19 Rotation of Gabapentinoids
• Vol. 1 No. 16 Dementia, Pain and Neuropsychiatric Behaviors
• Vol. 1 No. 11 Gabapentinoids and Respiratory Depression
• Vol. 1 No. 10 Gabapentinoids for Cancer-Related Neuropathy
• Vol. 1 No. 9 Gabapentinoids for Neuropathic Pain: Review
• Vol. 1 No. 4 Another Tool in your Palliative Care Toolbox: Lidocaine Series Part 3
• Vol. 1 No. 3 Another Tool in your Palliative Care Toolbox: Lidocaine Series Part 2
• Vol. 1 No. 2 Another Tool in your Palliative Care Toolbox: Lidocaine Series Part 1

• Vol. 1 No. 18 Review of Antipsychotic Characteristics to Aid in Antipsychotic Selection
• Vol. 1 No. 17 Atrial Fibrillation, Functionality, and Anticoagulation
• Vol. 1 No. 16 Dementia, Pain and Neuropsychiatric Behaviors
• Vol. 1 No. 6 Antipsychotic Adverse Drug Reactions: Focus on QTc Prolongation

• Vol. 4. No. 15 Gabapentinoids for Pruritis Review
• Vol. 5. No. 4 Disease related pruritis management

• Vol. 4 No. 5 Gabapentin: Updated Safety Concerns
• Vol. 1 No. 32 Gabapentin and Opioid Co-Administration
• Vol. 1 No. 11 Gabapentinoids and Respiratory Depression

• Vol. 3 No. 17 Safe Opioid Disposal Practices

• Vol. 1 No. 26 Prophylactic Scopolamine for Death Rattle

• Vol. 2 No. 8 Benzodiazepine Use for Delirium in Palliative Care
• Vol. 2 No. 6 Dexmedetomidine for Terminal Delirium
• Vol. 1 No. 32 Gabapentin and Opioid Co-Administration
• Vol. 1 No. 17 Atrial Fibrillation, Functionality, and Anticoagulation

• Vol. 2 No. 7 Benzodiazepine Class Review

• Vol. 2 No. 4 Neuroendocrine Tumors and Antidepressants

• Vol. 2 No. 14 Transmucosal Drug Delivery: A Focus on Opioids

• Vol. 2 No. 17 Steroids and Wound Healing

• Vol. 3 No. 20 UPMC Quality Improvement: Pilot Palliative Care Pharmacist-led Opioid Deprescribing
• Vol. 3 No. 14 UPMC Quality Improvement: Palliative Care Pharmacist Transitions of Care Interventions

2020

• Vol. 6 No. 14 Clinical Characteristics of Coronavirus Disease 2019 in China
• Vol. 6 No. 13 Do NSAIDs Worsen COVID-19?
• Vol. 6 No. 12 Breathing Problems with Gabapentin and Pregabalin
• Vol. 6 No. 11 Pharmacological Options for COVID-19
• Vol. 6 No. 10 Gabapentin Vs. Pregabalin: Showdown
• Vol. 6 No. 9 Opioids in Renal Dysfunction: Should Hydromorphone Be Preferred? Palliative Care’s Viewpoint
• Vol. 6 No. 8 Opioids in Renal Dysfunction: Should Hydromorphone Be Preferred? Oncology’s Viewpoint
• Vol. 6 No. 7 Opioids in Renal Dysfunction: Should Hydromorphone Be Preferred? Nephrology’s Viewpoint
• Vol. 6 No. 6 Opioids in Renal Dysfunction: Should Hydromorphone Be Preferred? Overview
• Vol. 6 No. 5 What’s New in Palliative Care Medications Drug #5: Istradefylline (Nourianz®)
• Vol. 6 No. 4 What’s New in Palliative Care Medications Drug #4: Bremelanotide (Vylessi®)
• Vol. 6 No. 3 What’s New in Palliative Care Medications Drug #3: Esketamine (Spravato®)
• Vol. 6 No. 2 What’s New in Palliative Care Medications Drug #2: Lemborexant (Dayvigo®)
• Vol. 6 No. 1 What’s New in Palliative Care Medications Drug #1: Prucalopride (Motegrity®)

2018

• Vol. 4 No. 48 Interaction Between PD-1 and PD-L1 Inhibitors and Steroids
• Vol. 4 No. 47 Refractory Acid Reflux Options for Treatment
• Vol. 4 No. 45 NSAIDs and SIADH: Caution?
• Vol. 4 No. 43 Mirtazapine and Weight Gain: Truth or False?
• Vol. 4 No. 40 Do Cranberry Products Prevent UTIs?
• Vol. 4 No. 37 The Management of Diabetes in Older Adults
• Vol. 4 No. 35 The Rational Pharmacological Treatment of Radiation Proctitis
• Vol. 4 No. 30 Should I Prescribe Vitamin B6 for Everyone Receiving Chemotherapy?
• Vol. 4 No. 26 Ouch That Hurts! Medications That Cause Pain Group #1: Boney Pain
• Vol. 4 No. 24 Managing Cancer-Related VTEs Question #3: When Should Anticoagulants Be Deprescribed?
• Vol. 4 No. 13 Bone Modifying Agents for Breast Cancer: 2017 Updated Guidelines
• Vol. 4 No. 10 Appetite Stimulants: What Should I Be Considering?
• Vol. 4 No. 4 What’s New in Palliative Care Medications (2017) Drug #4: Cariprazine (Vraylar®)
• Vol. 4 No. 3 What’s New in Palliative Care Medications (2017) Drug #3: Pimavanserin (Nuplazid®)
• Vol. 4 No. 2 What’s New in Palliative Care Medications (2017) Drug #2: Rexulti® (Brexpiprazole)

2017

• Vol. 3 No. 9 Antipsychotics and Delirium: To prescribe or not to prescribe?
• Vol. 3 No. 8 Appetite Stimulation: Megace or Dronabinol
• Vol. 3 No. 7 Cardiovascular Effects of CNS Stimulants
• Vol. 3 No. 6 Palliative Care Medications (2017) – Drug #6 Brexpiprazole (Rexulti®)